Fluoxetine in Pediatric Body Dysmorphic Disorder

Fluoxetine in Pediatric Body Dysmorphic Disorder

This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.

BDD usually begins in childhood or adolescence, but its treatment in pediatric populations has not been investigated. Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors (SRIs) such as fluoxetine (Prozac). Preliminary findings from case reports suggest that SRIs may also be effective in the treatment of BDD in children and adolescents. This study is the first large-scale, double-blind, placebo-controlled medication trial of fluoxetine for children and adolescents with BDD. Participants should be aged 16 or younger. Participation in this trial will last approximately 14 weeks.

Inclusion Criteria:

• Male or female children and adolescents aged 16 and younger
• BDD or its delusional variant present currently and for at least 6 months prior to the study
• Ability to communicate meaningfully with the investigators and competent to provide written assent

Exclusion Criteria:

• Presence of Schizophrenia or Bipolar Disorder
• Recent suicide attempt or suicidal ideations that warrant hospitalizations
• Previous allergic reaction to fluoxetine
• History of a seizure disorder